ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Roma, Lazio, ITA:

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine...

Enrolling
Smoldering Multiple Myeloma
Drug: Elranatamab

Phase 2

Stichting European Myeloma Network

Roma, Italy and 24 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Roma, Italy and 126 other locations

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Rome, Italy and 156 other locations

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM r...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Eftozanermin alfa

Phase 1

AbbVie
AbbVie

Rome, Lazio, Italy and 18 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Roma, Italy and 209 other locations

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Roma, Lazio, Italy and 40 other locations

combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...

Active, not recruiting
Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

Phase 1, Phase 2

Celgene
Celgene

Rome, Italy and 88 other locations

(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Belantamab mafodotin

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Roma, Lazio, Italy and 150 other locations

(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Drug: Dexamethasone
Drug: Bortezomib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Roma, Lazio, Italy and 129 other locations

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

Roma, Italy and 257 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems